Literature DB >> 9565007

Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators.

.   

Abstract

CONTEXT: Nonvalvular atrial fibrillation (AF) carries an increased risk for stroke, but absolute rates of stroke vary widely within the broad spectrum of AF patients.
OBJECTIVE: To prospectively validate a risk stratification scheme identifying patients with AF with low rates of stroke when given aspirin.
DESIGN: Prospective cohort study with mean duration of follow-up of 2.0 years, conducted between 1993 and 1997.
SETTING: Outpatient clinics affiliated with academic medical centers. PATIENTS: Patients with AF categorized as "low risk" based on the absence of 4 prespecified thromboembolic risk factors: recent congestive heart failure or left ventricular fractional shortening of 25% or less, previous thromboembolism, systolic blood pressure greater than 160 mm Hg, or female sex at age older than 75 years. INTERVENTION: All participants given aspirin, 325 mg/d. MAIN OUTCOME MEASURES: Ischemic stroke (considered disabling when Rankin score was II or worse 1-3 months later) and systemic embolism (primary events).
RESULTS: Among 892 participants, the mean (SD) age was 67 (10) years, 78% were men, and histories of hypertension, diabetes, and ischemic heart disease were present in 46%, 13%, and 16%, respectively. The rate of primary events was 2.2% per year (95% confidence interval [CI], 1.6%-3.0%), of ischemic stroke was 2.0% per year (95% CI, 1.5%-2.8%), and of disabling ischemic strokes was 0.8% per year (95% CI, 0.5%-1.3%). Those with a history of hypertension had a higher rate of primary events (3.6% per year) than those with no history of hypertension (1.1% per year) (P<.001). The rate of disabling ischemic stroke was low in those with and without a history of hypertension (1.4% per year and 0.5% per year, respectively). The rate of major bleeding during aspirin therapy was 0.5% per year.
CONCLUSION: Patients with AF who have relatively low rates of ischemic stroke, particularly disabling stroke, during treatment with aspirin can be reliably identified.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9565007

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  63 in total

1.  Development of a decision aid for atrial fibrillation who are considering antithrombotic therapy.

Authors:  M Man-Son-Hing; A Laupacis; A M O'Connor; R G Hart; G Feldman; J L Blackshear; D C Anderson
Journal:  J Gen Intern Med       Date:  2000-10       Impact factor: 5.128

2.  Long term anticoagulation or antiplatelet treatment. Only warfarin has been shown to reduce stroke risk in patients with atrial fibrillation.

Authors:  J G Cleland; G C Kaye
Journal:  BMJ       Date:  2001-07-28

3.  Toward a more practical decision analysis: a patient's perspective.

Authors:  A Parducci
Journal:  West J Med       Date:  2001-05

Review 4.  Idiopathic atrial fibrillation: prevalence, course, treatment, and prognosis.

Authors:  S L Kopecky
Journal:  J Thromb Thrombolysis       Date:  1999-01       Impact factor: 2.300

Review 5.  Risk factors for stroke and primary prevention of stroke in atrial fibrillation.

Authors:  A Laupacis; D Singer; A Jacobsen; M Dunn; J Dalen; G Albers
Journal:  J Thromb Thrombolysis       Date:  1999-01       Impact factor: 2.300

Review 6.  Evidence based cardiology: Prevention of ischaemic stroke.

Authors:  H J Barnett; M Eliasziw; H E Meldrum
Journal:  BMJ       Date:  1999-06-05

Review 7.  Use of oral anticoagulants in older patients.

Authors:  J L Sebastian; D D Tresch
Journal:  Drugs Aging       Date:  2000-06       Impact factor: 3.923

Review 8.  Prevention of cardioembolic stroke.

Authors:  William David Freeman; Maria I Aguilar
Journal:  Neurotherapeutics       Date:  2011-07       Impact factor: 7.620

9.  Ischemic Stroke Prevention.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-05       Impact factor: 3.598

Review 10.  Guidelines for stroke prevention in patients with atrial fibrillation.

Authors:  P A Howard
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.